双鹭药业：公司GLP-1长效产品正在整理和完善资料后准备上报，已在进行药品检验

Core Viewpoint - The company is preparing to submit the NDA for its GLP-1 long-acting product after addressing feedback and completing necessary documentation [2] Group 1 - Investors inquired about the delay in the NDA submission for the GLP-1 long-acting product, which has been pending for nearly a year [2] - The company confirmed that it is currently organizing and refining the required materials for the NDA submission and is conducting drug inspections [2] - The company will provide updates on the progress of the NDA submission as new developments arise [2]